KFDA approved Lyrica for neuropathic pain.

Pfizer Korea said that the KFDA approved Lyrica (pregabalin) for neuropathic pain associated with diabetic peripheral neuropathy and adjunctive therapy in the treatment of partial seizures in adults on June 14.

Lyrica shows a new mode of action by selectively binding with alpha 2 delta protein that regulates a nerve pathway of brain and spinal cord to normalize overstimulated nerve cells rel...